C12N 2501/51
B7 molecules
Official title: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
C12N2501/51 (B7 molecules) appears on 310 US grants and 688 published applications in this corpus.
Search patents in C12N- Granted patents
- 310
- Published applications
- 688
- Assignees
- 325
- Inventors
- 1,211
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 4 | 2 |
| 2002 | 5 | 13 |
| 2003 | 2 | 23 |
| 2004 | 4 | 17 |
| 2005 | 5 | 11 |
| 2006 | 4 | 11 |
| 2007 | 2 | 5 |
| 2008 | 4 | 5 |
| 2009 | 7 | 10 |
| 2010 | 14 | 23 |
| 2011 | 14 | 24 |
| 2012 | 13 | 17 |
| 2013 | 4 | 16 |
| 2014 | 18 | 16 |
| 2015 | 15 | 17 |
| 2016 | 10 | 20 |
| 2017 | 11 | 24 |
| 2018 | 11 | 31 |
| 2019 | 19 | 38 |
| 2020 | 21 | 46 |
| 2021 | 23 | 60 |
| 2022 | 14 | 57 |
| 2023 | 20 | 63 |
| 2024 | 20 | 59 |
| 2025 | 22 | 56 |
| 2026 | 22 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Process for producing donor-batched cells expressing a recombinant receptor11 Aug 2026US 12,703,733 B2Juno Therapeutics, Inc.
- Methods for engineering allogeneic and highly active T cell for immunotheraphy14 Jul 2026US 12,680,076 B2Cellectis
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion7 Jul 2026US 12,673,982 B2Iovance Biotherapeutics, Inc.
- FOXP3 engineered CD4+ T cells for use in treg-based immunotherapy7 Jul 2026US 12,674,137 B2Fondazione Telethon
- Method for expansion of double negative regulatory T cells30 Jun 2026US 12,668,778 B2University Health Network
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion17 Sep 2026US 2026/0274920 A1Iovance Biotherapeutics, Inc.
- Systems and apparatuses for cellular therapeutics manufacture27 Aug 2026US 2026/0250617 A1Bruker Spatial Biology, Inc.
- T-cells comprising chimeric antigen receptors and compositions thereof for treatment of cancer20 Aug 2026US 2026/0241001 A1King Faisal Specialist Hospital & Research Centre
- Methods for culturing cells and kits and apparatus for same20 Aug 2026US 2026/0242729 A1Juno Therapeutics, Inc.
- Method for obtaining regulatory t cells derived from thymic tissue and use of said cells as cell immunotherapy in immune system disorders20 Aug 2026US 2026/0242733 A1Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005